Who is sponsoring NCT00794586?

NCT00794586 is sponsored by Gilead Sciences.

What condition does NCT00794586 study?

NCT00794586 studies Cystic Fibrosis.

What drugs are being tested in NCT00794586?

Interventions: FTI, AZLI, Placebo, AZLI.

What is the status of NCT00794586?

NCT00794586 is currently COMPLETED.

Last reviewed 2013-12-03 · How we verify

A Phase 2, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Fosfomycin/Tobramycin for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa

NCT00794586 Phase 2 COMPLETED

The purpose of this study is to evaluate the safety and efficacy of 2 dose combinations of fosfomycin/tobramycin for inhalation (FTI), following a 28-day course of Aztreonam for Inhalation (AZLI) in patients with cystic fibrosis and Pseudomonas aeruginosa lung infection.

Details

Lead sponsor	Gilead Sciences
Phase	Phase 2
Status	COMPLETED
Enrolment	120
Start date	2008-11
Completion	2010-03

Conditions

Cystic Fibrosis

Interventions

FTI, AZLI
Placebo, AZLI

Primary outcomes

Relative change in lung function from baseline at Day 28. — 28 Days

Countries

United States